ClinicalTrials.gg

Program

roginolisib

Also written as “IOA-244” and “Roginolisib”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Primary Myelofibrosis · Uveal Melanoma · Carcinoma, Non-Small-Cell Lung, led by iOnctura.

Furthest: phase 2, since Nov 18, 20244 company-led studies, 4 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
iOnctura44 open or runningphase 2since Nov 18, 2024Mar 11, 2020Jan 2027phase 2 · NCT06879717

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04328844 · 210 enrolled · Italy, United Kingdom
  2. Nov 18, 2024Phase 2 study in Uveal MelanomaNCT06717126 · 85 enrolled · Italy, Spain, United Kingdom
  3. Feb 26, 2025Phase 2 study in Primary MyelofibrosisNCT06887803 · 26 planned · Italy, Spain, United Kingdom
  4. Mar 5, 2025Phase 2 study in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06879717 · 45 enrolled · Belgium, Italy, Spain

Ahead

  1. Jan 2027Primary completion: phase 2 study in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06879717
  2. Dec 2027Primary completion: phase 2 study in Uveal MelanomaNCT06717126
  3. Mar 2028Primary completion: phase 2 study in Primary MyelofibrosisNCT06887803

TargetBeta

PIK3CD →read by rule
“A Phase 1/2, Open Label, Study of Roginolisib (IOA-244), an Orally Bioavailable, Selective PI3Kδ Inhibitor in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) in Combination With Venetoclax and Rituximab”study text, by rule · the study

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
idelalisibruleGilead Sciencesphase 428
duvelisibruleSecuraBiophase 326
leniolisibrulePharming Groupphase 39
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06879717Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · Belgium, Italy, Spain2Active, not recruitingJan 202745
NCT06887803Primary Myelofibrosis · Italy, Spain, United Kingdom2RecruitingMar 202826
NCT06717126Uveal Melanoma · Italy, Spain, United Kingdom2Active, not recruitingDec 202785
NCT04328844Lymphoma, Non-Hodgkin · Italy, United Kingdom1Active, not recruitingDec 13, 2023210

How it is read

Names in the registry

  • “roginolisib”, 2 entries
  • “IOA-244”, 1 entry
  • “Roginolisib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.